| Document |
Document Title |
|
JPH11158120A |
To obtain a prostaglandin(PG) by a method which allows to enlarge variation in α- and co-chains of PG skeleton i.e., the reaction of a specific methylcyclopentanone derivative with a specific compound, a specific acid anhydride, and so ...
|
|
JPH11505802A |
The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by formula (I), wherein wavy line attachments indicate either the ...
|
|
JP2893812B2 |
Compounds of the following formula are stable and potent analogues of prostacyclin. e
|
|
JP2883446B2 |
Higher order cuprate complexes are prepared by means of a transmetalation from a corresponding zirconate intermediate. This process is particularly valuable with respect to the preparation of vinylic side chains such as are present in pr...
|
|
JP2885386B2 |
An improved process for isolating organic compounds from crude product or reaction mixtures by dissolving said crude product or reaction mixture in a suitable solvent, contacting the resulting solution with a lithium salt to form a solid...
|
|
JP2881473B2 |
|
|
JPH1143461A |
To obtain the subject new compound having osteogenesis promoting activity. This new compound is shown by formula I [R1 is a halogen, etc.; R2 is a group of the formula (CH2)qY2rR5 (Y2 is O, etc.; R5 is H, etc.; (r) is 0 or 1; (q) is 0-5)...
|
|
JP2855450B2 |
|
|
JP2852057B2 |
Use of derivatives of a diastereomer of prostaglandin F2alpha, viz. 11 epi, for the manufacture of compositions for the treatment of glaucoma or ocular hypertension.
|
|
JP2849608B2 |
|
|
JPH1112249A |
To obtain the subject new compound having adverse effect lower than that of a conventional prostaglandin(PG) E analogue, having strong anti- ulcer action excellent in persistency and having triple bond at 13 and 14 positions and having s...
|
|
JP2840457B2 |
A process for synthesizing prostaglandin E1, E2 and derivatives thereof is provided. The process is a "one-pot" method in which 2-furyllithium, copper cyanide, a lower alkyllithium reagent and either an (E)-alkenylstannane or a halogenid...
|
|
JP2839841B2 |
|
|
JP2836117B2 |
|
|
JP2818381B2 |
PURPOSE: To obtain the subject compound inhibiting cell migration induced by a chemokine such as monocyte migration factor, MCP-1/MCAF, thus useful as a medicine for arteriosclerosis, etc., by using a specific organolithium compound, etc...
|
|
JPH10265454A |
To obtain the subject compound having strong bond of prostaglandin E2 receptor to subsidiary type EP4 and useful for prevention and/or treatment of immunologic diseases, etc. This compound is represented by formula I [R1 is OH, a 1-4C al...
|
|
JPH10259179A |
To obtain the subject new compound having a multi-substituted aryloxy group on the ω chain of a prostaglandin and useful for preventing and treating eye diseases. A compound of the formula [A is vinylene group, etc.; B is CH(OR3), etc.;...
|
|
JP2802912B2 |
|
|
JP2791544B2 |
Disclosed is the use of cloprostenol, fluprostenol, their analogues and their pharmaceutically acceptable salts and esters for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said ...
|
|
JP2786437B2 |
PCT No. PCT/DE87/00513 Sec. 371 Date Jul. 13, 1988 Sec. 102(e) Date Jul. 13, 1988 PCT Filed Nov. 12, 1987 PCT Pub. No. WO88/03567 PCT Pub. Date May 19, 1988.Process for the production of optically active (+)-bicyclo[3.3.0]octanol derivat...
|
|
JPH10506893A |
Disclosed are 9-deoxyprostaglandins which are useful in the treatment of glaucoma and ocular hypertension. Some of these 9-deoxyprostaglandins are novel. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostagl...
|
|
JPH10182598A |
To provide a method for producing a fluorine-containing prostaglandin derivative having high activities as a medicine and further having fluorine atom at 15-position having no side effect by allowing specific phosphoranes to act on a spe...
|
|
JP2769294B2 |
PURPOSE: To obtain the subject composition which contains a specific prostaglandin homologue as an active ingredient and can lower intraocular pressure accompanied by no side effect. CONSTITUTION: This composition contains (A) ophthalmol...
|
|
JP2760514B2 |
|
|
JP2756689B2 |
Pharmaceutical or veterinary preparations for use in the treatment of thromboxane A2 mediating diseases, comprising a pharmacologically effective amount of at least one compound of the formula: wherein R<1> is carboxyl or 5-tetrazolyl, R...
|
|
JP2746800B2 |
PURPOSE:To suppress the production of trans-type DELTA<5>-PGs formed as a by- product and obtain the subject intermediate by reacting a specific lactol with a ylide in a specific ethereal or an aromatic solvent. CONSTITUTION:A lactol exp...
|
|
JPH1087607A |
To obtain a new fluorine-containing prostaglandin derivative convertible into a physiologically active 15-deoxy-15-fluoroprostaglandin F derivative. This fluorine-containing prostaglandin derivative is expressed by the formula I [A is et...
|
|
JP2736066B2 |
PCT No. PCT/DE87/00513 Sec. 371 Date Jul. 13, 1988 Sec. 102(e) Date Jul. 13, 1988 PCT Filed Nov. 12, 1987 PCT Pub. No. WO88/03567 PCT Pub. Date May 19, 1988.Process for the production of optically active (+)-bicyclo[3.3.0]octanol derivat...
|
|
JP2721414B2 |
The present invention relates to the use of certain prostaglandin derivatives for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension. It also relates to a respective opthalmological composition.
|
|
JP2716986B2 |
9-Halogen-(Z)-prostane derivatives have the formula (I), where Z is one of the residues (a) or (b), Hal is a chorine or fluorine atom in the alpha or beta position, R1 is the residue CH2OH or (c) where R2 is a hydrogen atom or an alkyl, ...
|
|
JPH1017561A |
To industrially advantageously obtain the subject new alcohol compound important as an intermediate for prostaglandins from easily available raw materials in advantageous productivity by stereospecifically reducing an α,β-unsaturated k...
|
|
JPH107574A |
To obtain an endothelin antagonist for eye drop containing 15 keto- prostaglandin F compound as an active ingredient and useful for treating various diseases and morbid state in which endothelin participates. This endothelin antagonist c...
|
|
JP2677779B2 |
|
|
JPH09286775A |
To obtain a new prostaglandin derivative having a strong intraocular pressure lowering activity, and useful for treating various diseases or symptoms attributable to the increase of intraocular pressure including glaucoma. A prostaglandi...
|
|
JP2670545B2 |
This invention relates to the novel processes for the preparation of a 16-methoxy-16-methyl prostaglandin E1 derivative and to the novel intermediates useful therefor.
|
|
JP2670521B2 |
Method for preparing 13,14-dihydro-17-phenyl analogues of PGF2 alpha or PGE2 comprising the step of hydrogenating the double bond in an intermediate compound (I) without deoxygenation of the allylic alcohol to give one of the intermediat...
|
|
JP2667875B2 |
This invention encompasses a process for preparing higher order cuprate complexes which contain a carbanion for the formation of carbon to carbon bonds in reactions such as 1,4-conjugate addition. The complex is formed by reacting a firs...
|
|
JP2654834B2 |
|
|
JP2641622B2 |
|
|
JP2637339B2 |
PURPOSE: To safely obtain a compound in high yield using, as solvent, N-methyl-2- pyrrolidone harmless to human health, through such a three-component continuous process as conjugate addition reaction between a 4-substituted-2-cyclopente...
|
|
JP2634787B2 |
PURPOSE: To obtain the subject novel compound exhibiting antihypertensive, bronchodilatative and antithrombotic functions or the like, and useful for, e.g. prevention or treatment of coronary heart disease, or inhibition of bronchial str...
|
|
JP2635213B2 |
The invention relates to a novel process for the preparation of 13,14-dihydro-15 (R)-17-phenyl-18,19,20-trinor-PGF2 alpha isopropyl ester of the formula (I)-wherein R stands for saturated or unsaturated straight, branched or cyclic C1-7 ...
|
|
JP2621122B2 |
|
|
JP2620558B2 |
|
|
JP2608948B2 |
The invention concerns a process for producing E/Z mixtures of 2-(bicyclo[3.3.0]octane-3-ylidene) acetic acid derivatives of formula (I) in which either the E or the Z moiety predominates.
|
|
JPH09124593A |
To obtain the subject compound having weak hypotensive effect in spite of having strong and continuous blood flow increasing action and useful for treatment, etc., of peripheral circulatory disorder by esterifying a carboxylic acid at 1 ...
|
|
JP2608089B2 |
A 2-cyclopentenone derivative represented by the following formula wherein R<1> represents an alkyl group having 1 to 10 carbon atoms which may be substituted by a substituted or unsubstituted phenyl or phenoxy group, R<2>, R<3>, R<4> an...
|
|
JP2605123B2 |
|
|
JP2602964B2 |
The present invention provides a novel prostaglandin analogue of the following formula: and a method for its preparation.o
|
|
JPH09504029A |
Compounds of the formula where the hatched lines indicate alpha ( alpha ) configuration, a solid triangle is used to indicate beta ( beta ) configuration, lines on both sides of a double bond indicate cis (Z) configuration, and lines on ...
|
